Biomarkers of an Autoimmune Skin Disease—Psoriasis

Abstract

Psoriasis is one of the most prevalent autoimmune skin diseases. However, its etiology and pathogenesis are still unclear. Over the last decade, omics-based technologies have been extensively utilized for biomarker discovery. As a result, some promising markers for psoriasis have been identified at the genome, transcriptome, proteome, and metabolome level. These discoveries have provided new insights into the underlying molecular mechanisms and signaling pathways in psoriasis pathogenesis. More importantly, some of these markers may prove useful in the diagnosis of psoriasis and in the prediction of disease progression once they have been validated. In this review, we summarize the most recent findings in psoriasis biomarker discovery. In addition, we will discuss several emerging technologies and their potential for novel biomarker discovery and diagnostics for psoriasis.

From randomized clinical trials to real life data. An Italian clinical experience with ixekizumab and its management

“…Psoriasis is a systemic inflammatory disease characterized by a growing body of comorbidities; however availability of targeted anti‐psoriatic therapy has been largely limited (Al‐Mutairi, Al‐Farag, Al‐Mutairi, & Al‐Shiltawy, ; Asa'ad, Fiore, Alfieri, et al, ; Fiore, Leone, Maraolo, et al, ; Jiang, Hinchliffe, & Wu, ; Santus, Rizzi, Radovanovic, et al, ; Yadav, Singh, & Singh, ). More recently, clinicians have been able to better treat psoriasis due to the development of targeted therapy allowing for: (a) second‐step therapy in moderate to severe psoriasis, (b) treatment of moderate to severe psoriasis in patients which have contraindication for traditional systemic drugs and/or (c) treatment of mild psoriasis not responsive to topical treatments (Ighani et al, ).…”

Serum vascular endothelial growth factor receptor 3 as a potential biomarker in psoriasis

“…Biomarkers could potentially aid in the diagnosis of psoriasis, tracking disease progression and monitoring of response to treatments. Potential serum biomarkers have been investigated during the past decades, such as tumor necrosis factor alpha, interferon gamma, interleukin 6 (IL‐6), IL‐8, IL‐12, IL‐18, C‐reactive protein, complement component 3, 4 (C3, C4), platelet P selectin and heat‐shock protein 60 . There is not, however, a clinical, usable biomarker that could aid in monitoring the severity of psoriasis.…”

How Does Chronic Cigarette Smoke Exposure Affect Human Skin? A Global Proteomics Study in Primary Human Keratinocytes

“…Our group has investigated global proteomic alterations in oral keratinocytes that are chronically exposed to chewing tobacco in vitro and identified significant dysregulation in key metabolic pathways (Nanjappa et al, 2015). High-throughput investigations of skin diseases such as eczema and psoriasis have aided in a greater understanding of the underlying genetic and/or molecular basis of disease pathologies (Cole et al, 2014;Jiang et al, 2015;Kang et al, 2016). In addition, computational systems biology approaches that integrate data from large ''omics'' datasets can aid in gaining mechanistic insights into disease pathology (Sevimoglu and Arga, 2015).…”